| scholarly article | Q13442814 |
| P2093 | author name string | Li Li | |
| Yan Sun | |||
| Bin Zhao | |||
| Yang Zhao | |||
| Haitao Niu | |||
| Long Sheng | |||
| Dongfang Huang | |||
| P2860 | cites work | Estrogen receptors in breast carcinogenesis and endocrine therapy | Q38272598 |
| A Comprehensive Outline of Trastuzumab Resistance Biomarkers in HER2 Overexpressing Breast Cancer. | Q38603191 | ||
| Cancer Statistics, 2017. | Q39038674 | ||
| PI3K-AKT-mTOR inhibitors in breast cancers: From tumor cell signaling to clinical trials | Q39143000 | ||
| Predictive and prognostic significance of p27, Akt, PTEN and PI3K expression in HER2-positive metastatic breast cancer | Q41100418 | ||
| Impact of somatic PI3K pathway and ERBB family mutations on pathological complete response (pCR) in HER2-positive breast cancer patients who received neoadjuvant HER2-targeted therapies. | Q41149668 | ||
| Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt Is required for antibody-mediated effects on p27, cyclin D1, and antitumor action | Q42523855 | ||
| Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study | Q43121691 | ||
| Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parall | Q43180234 | ||
| Down regulation of bcl2 expression in invasive ductal carcinomas is both estrogen- and progesterone-receptor dependent and associated with poor prognostic factors | Q43982716 | ||
| PI3KCA mutations and/or PTEN loss in Her2-positive breast carcinomas treated with trastuzumab are not related to resistance to anti-Her2 therapy. | Q44585456 | ||
| Combined trastuzumab and paclitaxel treatment better inhibits ErbB-2-mediated angiogenesis in breast carcinoma through a more effective inhibition of Akt than either treatment alone | Q44595949 | ||
| Bcl-2 expression predicts local relapse for early-stage breast cancer receiving conserving surgery and radiotherapy | Q46564173 | ||
| Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors. | Q46966638 | ||
| SOX11 promotes tumor angiogenesis through transcriptional regulation of PDGFA in mantle cell lymphoma. | Q48284944 | ||
| Hormone-receptor expression and activity of trastuzumab with chemotherapy in HER2-positive advanced breast cancer patients. | Q54588529 | ||
| TP53 genomics predict higher clinical and pathologic tumor response in operable early-stage breast cancer treated with docetaxel-capecitabine ± trastuzumab | Q59565353 | ||
| Apoptosis and Bbcl-2 expression in gastric carcinomas: correlation withclinicopathological variables, p53 expression, cell proliferation and prognosis | Q77716906 | ||
| An automated method for finding molecular complexes in large protein interaction networks | Q21284295 | ||
| Hallmarks of Cancer: The Next Generation | Q22252312 | ||
| BCL2 in breast cancer: a favourable prognostic marker across molecular subtypes and independent of adjuvant therapy received | Q24610409 | ||
| PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. | Q27824819 | ||
| A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer | Q27851414 | ||
| Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets | Q28140238 | ||
| Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells | Q28201813 | ||
| Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial | Q28254919 | ||
| Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer | Q29616112 | ||
| Genomic characteristics of trastuzumab-resistant Her2-positive metastatic breast cancer. | Q33840864 | ||
| Targeting Bcl-2 in Herceptin-Resistant Breast Cancer Cell Lines | Q35599629 | ||
| HER2 therapy: molecular mechanisms of trastuzumab resistance. | Q35633712 | ||
| High basal Wnt signaling is further induced by PI3K/mTor inhibition but sensitive to cSRC inhibition in mammary carcinoma cell lines with HER2/3 overexpression | Q35709435 | ||
| Adjuvant trastuzumab in HER2-positive breast cancer | Q35710898 | ||
| High-resolution chromatin immunoprecipitation (ChIP) sequencing reveals novel binding targets and prognostic role for SOX11 in mantle cell lymphoma. | Q35878937 | ||
| Upregulation of ER Signaling as an Adaptive Mechanism of Cell Survival in HER2-Positive Breast Tumors Treated with Anti-HER2 Therapy. | Q36021424 | ||
| Prospective Biomarker Analysis of the Randomized CHER-LOB Study Evaluating the Dual Anti-HER2 Treatment With Trastuzumab and Lapatinib Plus Chemotherapy as Neoadjuvant Therapy for HER2-Positive Breast Cancer | Q36064908 | ||
| Mechanisms of trastuzumab resistance and their clinical implications. | Q36355193 | ||
| Whole-transcriptome analysis links trastuzumab sensitivity of breast tumors to both HER2 dependence and immune cell infiltration | Q36414012 | ||
| Multicenter phase II study of neoadjuvant lapatinib and trastuzumab with hormonal therapy and without chemotherapy in patients with human epidermal growth factor receptor 2-overexpressing breast cancer: TBCRC 006 | Q36810717 | ||
| BCL2 as a Subtype-Specific Prognostic Marker for Breast Cancer | Q37316599 | ||
| Biomarker analysis of the NeoSphere study: pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel for the neoadjuvant treatment of HER2-positive breast cancer | Q37633741 | ||
| Prognostic Influence of BCL2 on Molecular Subtypes of Breast Cancer | Q37735963 | ||
| P4510 | describes a project that uses | Cytoscape | Q3699942 |
| P433 | issue | 1 | |
| P304 | page(s) | 139-146 | |
| P577 | publication date | 2018-05-07 | |
| P1433 | published in | Molecular Medicine Reports | Q26842180 |
| P1476 | title | Alterations in mRNA profiles of trastuzumab‑resistant Her‑2‑positive breast cancer | |
| P478 | volume | 18 |
Search more.